113 related articles for article (PubMed ID: 20202838)
1. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.
Donnell AF; Dollings PJ; Butera JA; Dietrich AJ; Lipinski KK; Ghavami A; Hirst WD
Bioorg Med Chem Lett; 2010 Apr; 20(7):2163-7. PubMed ID: 20202838
[TBL] [Abstract][Full Text] [Related]
2. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
[TBL] [Abstract][Full Text] [Related]
3. Discovery of triazines as selective PDE4B versus PDE4D inhibitors.
Hagen TJ; Mo X; Burgin AB; Fox D; Zhang Z; Gurney ME
Bioorg Med Chem Lett; 2014 Aug; 24(16):4031-4. PubMed ID: 24998378
[TBL] [Abstract][Full Text] [Related]
4. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
[TBL] [Abstract][Full Text] [Related]
5. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
6. Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode.
Kranz M; Wall M; Evans B; Miah A; Ballantine S; Delves C; Dombroski B; Gross J; Schneck J; Villa JP; Neu M; Somers DO
Bioorg Med Chem; 2009 Jul; 17(14):5336-41. PubMed ID: 19525117
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective PDE4B inhibitors.
Naganuma K; Omura A; Maekawara N; Saitoh M; Ohkawa N; Kubota T; Nagumo H; Kodama T; Takemura M; Ohtsuka Y; Nakamura J; Tsujita R; Kawasaki K; Yokoi H; Kawanishi M
Bioorg Med Chem Lett; 2009 Jun; 19(12):3174-6. PubMed ID: 19447034
[TBL] [Abstract][Full Text] [Related]
8. Rhodanine derivatives as novel inhibitors of PDE4.
Irvine MW; Patrick GL; Kewney J; Hastings SF; MacKenzie SJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):2032-7. PubMed ID: 18304812
[TBL] [Abstract][Full Text] [Related]
9. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
[TBL] [Abstract][Full Text] [Related]
10. Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
Lacombe P; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Gallant M; Girard Y; Huang Z; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini JA; Masson P; Nicholson DW; Nicoll-Griffith DA; Salem M; Styhler A; Young RN
Bioorg Med Chem Lett; 2009 Sep; 19(17):5266-9. PubMed ID: 19640717
[TBL] [Abstract][Full Text] [Related]
11. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
13. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
[TBL] [Abstract][Full Text] [Related]
15. Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity.
Biagini P; Biancalani C; Graziano A; Cesari N; Giovannoni MP; Cilibrizzi A; Dal Piaz V; Vergelli C; Crocetti L; Delcanale M; Armani E; Rizzi A; Puccini P; Gallo PM; Spinabelli D; Caruso P
Bioorg Med Chem; 2010 May; 18(10):3506-17. PubMed ID: 20413313
[TBL] [Abstract][Full Text] [Related]
16. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Gangwal RP; Damre MV; Das NR; Dhoke GV; Bhadauriya A; Varikoti RA; Sharma SS; Sangamwar AT
J Mol Graph Model; 2015 Apr; 57():89-98. PubMed ID: 25687765
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.
Kuang R; Shue HJ; Blythin DJ; Shih NY; Gu D; Chen X; Schwerdt J; Lin L; Ting PC; Zhu X; Aslanian R; Piwinski JJ; Xiao L; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Minnicozzi M; Billah M; Wang P
Bioorg Med Chem Lett; 2007 Sep; 17(18):5150-4. PubMed ID: 17683932
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.
Kagayama K; Morimoto T; Nagata S; Katoh F; Zhang X; Inoue N; Hashino A; Kageyama K; Shikaura J; Niwa T
Bioorg Med Chem; 2009 Oct; 17(19):6959-70. PubMed ID: 19744860
[TBL] [Abstract][Full Text] [Related]
19. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
20. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
